Kymab Announces Publication of the Kymouse Technology in Nature Biotechnology

Kymab Announces Publication of theKymab Announces Publication of the Kymouse Technology in Nature Biotechnology PR Newswire CAMBRIDGE, England, March 16, 2014 Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse™ (http://dx.doi.org/). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this new technology Kymouse™. They have demonstrated that these mice develop an enormous range of human antibodies which can be developed as potent drugs to treat a variety of human diseases such as cancer, autoimmune and infectious diseases. Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate all its attributes. Professor Allan Bradley, Founder and Chief Scientific Officer of Kymab, said: Dr Christian Grøndahl, Chief Executive Officer of Kymab, added: "We are reviewed publication of transgenic mice with a fully human antibody repertoire.